Study suggests statins reduce cardiovascular risk for people with type 2 diabetes

August 19, 2004

Results of a randomised trial in this week's issue of THE LANCET suggest that people with type 2 diabetes could benefit from cholesterol-lowering therapy with statins to reduce the risk of cardiovascular disease--even when they do not have high cholesterol concentrations.

Many recent studies have shown the benefits of statin therapy to reduce the risk of cardiovascular disease in various groups of patients. Whether most patients with diabetes (who are known to be at increased cardiovascular risk) should receive cholesterol-lowering therapy remains unclear, especially for those patients who do not have High cholesterol.

Helen Colhoun (University College Dublin, Ireland, formerly at University College London ) and colleagues assess the effectiveness of atorvastatin for the primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-('bad') cholesterol. Around 2800 patients (aged 40-75 years) in 132 centres in the UK and Ireland were randomly assigned either placebo (1410 patients) or atorvastatin (1428 patients). Patients had no previous history of cardiovascular disease and had low LDL cholesterol concentrations (around 4 millimoles per litre or less).

Average follow-up was around 4 years after study enrolment. The primary outcome measure of the study--acute coronary heart disease events, coronary revascularisation, or stroke--was reduced by around a third among patients given atorvastatin compared with those given placebo. Atorvastatin reduced the death rate by 27% compared with placebo. Strokes were reduced by 48%.

Professor Colhoun comments: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld.

In an accompanying commentary (p 641), Abhimanyu Garg (University of Texas, USA) concludes: "While landmark trials like CARDS increase our confidence in lipid-lowering drug therapy for prevention of coronary heart disease in patients with type 2 diabetes, it is still prudent to assess an individual's risk-benefit ratio before recommending long-term statin therapy. Thus more models need to be developed, such as the UK Prospective Diabetes Study risk engine, to assess coronary heart disease risk in patients with type 2 diabetes. For patients with type 2 diabetes at moderate to low risk of coronary heart disease, maximal lowering of lipids with diet, exercise, weight loss, and rigorous glycaemic control must be attempted before considering lipid-lowering drugs".
-end-
Contact: Professor Helen Colhoun c/o Nita Ares, Ketchum, T) 44-207-611-3664; M) 44-781-842-1415; Nita.Ares@ketchum.com

Professor Abhimanyu Garg, Division of Nutrition and Metabolic Diseases, Center for Human Nutrition, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9052, USA; T) +1 214 648 2895; abhimanyu.garg@utsouthwestern.edu

Lancet

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.